The National Science Foundation awarded a $255,957 STTR Phase I Project Grant to CHS Healthcare Ventures Inc., doing business as Lightengale, to develop a lighted infusion line to optimize care and decrease complications for critically ill patients in infectious isolation situations such as COVID-19. The grant is funded through the NSF's Technology, Innovation, and Partnerships program (CFDA 47.084) and aims to advance science and engineering research leading to breakthrough technologies and solutions to national challenges. Under the award, Lightengale will deliver a lighted intravenous infusion line to improve monitoring of critically ill patients who must be isolated due to infectious disease. The system is intended to enhance care for patients suffering from conditions like COVID-19 while protecting healthcare workers from exposure. The project is scheduled for completion by March 31, 2023 and will be performed in Decatur, Georgia.
Generated 1/7/24, 12:05 PM